These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15378282)

  • 1. Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?
    Madjd Z; Durrant LG; Pinder SE; Ellis IO; Ronan J; Lewis S; Rushmere NK; Spendlove I
    Cancer Immunol Immunother; 2005 Feb; 54(2):149-56. PubMed ID: 15378282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues.
    Thorsteinsson L; O'Dowd GM; Harrington PM; Johnson PM
    APMIS; 1998 Sep; 106(9):869-78. PubMed ID: 9808413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and regulation by interferon-gamma of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours.
    Schmitt CA; Schwaeble W; Wittig BM; Meyer zum Büschenfelde KH; Dippold WG
    Eur J Cancer; 1999 Jan; 35(1):117-24. PubMed ID: 10211099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis.
    Gorter A; Blok VT; Haasnoot WH; Ensink NG; Daha MR; Fleuren GJ
    Lab Invest; 1996 Jun; 74(6):1039-49. PubMed ID: 8667608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study.
    Liu M; Yang YJ; Zheng H; Zhong XR; Wang Y; Wang Z; Wang YG; Wang YP
    Oncol Rep; 2014 Dec; 32(6):2619-27. PubMed ID: 25241923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
    Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
    J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer.
    Rushmere NK; Knowlden JM; Gee JM; Harper ME; Robertson JF; Morgan BP; Nicholson RI
    Int J Cancer; 2004 Mar; 108(6):930-6. PubMed ID: 14712499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complement regulatory proteins CD55 (decay accelerating factor) and CD59 are expressed on the inner acrosomal membrane of human spermatozoa as well as CD46 (membrane cofactor protein).
    Cummerson JA; Flanagan BF; Spiller DG; Johnson PM
    Immunology; 2006 Jul; 118(3):333-42. PubMed ID: 16827894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.
    Koretz K; Brüderlein S; Henne C; Möller P
    Br J Cancer; 1993 Nov; 68(5):926-31. PubMed ID: 7692919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of CD59 expression in breast tumours correlates with poor survival.
    Madjd Z; Pinder SE; Paish C; Ellis IO; Carmichael J; Durrant LG
    J Pathol; 2003 Aug; 200(5):633-9. PubMed ID: 12898600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of the complement regulatory proteins in the human eye.
    Bora NS; Gobleman CL; Atkinson JP; Pepose JS; Kaplan HJ
    Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3579-84. PubMed ID: 7505007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic immunohistochemical analysis of the expression of CD46, CD55, and CD59 in colon cancer.
    Shang Y; Chai N; Gu Y; Ding L; Yang Y; Zhou J; Ren G; Hao X; Fan D; Wu K; Nie Y
    Arch Pathol Lab Med; 2014 Jul; 138(7):910-9. PubMed ID: 24978917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
    Ravindranath NM; Shuler C
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
    Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
    Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells.
    Iborra A; Mayorga M; Llobet N; Martínez P
    Cell Immunol; 2003 May; 223(1):46-51. PubMed ID: 12914757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
    Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
    FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.